Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2018; 64(4): 82-90


MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE LESIONS IN RAT BRAIN UNDER MODELING OF PARKINSON’S LIKE SYNDROME: CORRECTIVE ACTION OF CAPICOR

I.M. Mankovska1, O.O. Gonchar1, V.I. Nosar1, K.V. Rozova1, L.V. Bratus1, E.E. Kolesnikova1, Yu.V. Putii1, I.M. Karaban2

  1. O.O.Bogomoletz Institute of Physiology of the National Academy of Sciences of Ukraine, Kyiv, Ukraine
  2. D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz64.04.082

Abstract

It was studied the influence of Capicor (containing Meldonium dihydrate and gamma-butyrobetain dehydrate) on morphofunctional state, pro- and antioxidant balance, respiration and phosphorylation in rat brain mitochondria under rotenone-induced Parkinson’s-like syndrome. It was shown that this syndrome is characterized by destructive changes in mitochondrial structure, the mitochondrial dynamic perturbations in striatum, the marked disturbances of pro- and antioxidant balance as well as of respiration and phosphorylation in brain mitochondria. After Capicor administration, there was demonstrated the positive changes in mitochondrial structure with an increase in mitochondrial total number and a decrease in the number of damaged mitochondria in striatum. Under the action of Capicor, there was demonstrated a reduction in oxidative stress expressiveness in brain mitochondria with a decrease in TBA-active products content, a rise in glutathione peroxidase and Mn-SOD activities. After Capicor administration, there was shown the significant increase in mitochondrial respiration rate (V3) as well as in effectiveness of ATP synthesis (V3/V4 ATP, ADP/O). So, Capicor is shown to be effective in the reduction of mitochondrial dysfunction and oxidative disturbances in rat brain mitochondria under rotenone induced Parkinson’s-like syndrome.

Keywords: Parkinson’s-like syndrome; mitochondrial dysfunction; oxidative stress; Capicor.

References

  1. Frank C, Pari G, Rossiter JP. Approach to diagnosis of Parkinson disease. Can Fam Physician. 2006;52: 862-68. PubMed PubMedCentral
  2.  
  3. Hudson G. The ageing brain, mitochondria and neurodegeneration. Mitochondria dysfunction in neurodegenerative disorders. Springer Int Publishing. 2016;59-80. CrossRef   Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003; 53 (suppl 3):S26-36 CrossRef PubMed  
  4. Chaturvedi RK, Beal M. Mitochondrial approaches for neuroprotection. Ann NY Acad Sci. 2008;1147:395-412. CrossRef PubMed PubMedCentral
  5.  
  6. Langston JW, Ballard P, Tetrud JW, Irvin I. Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science. 1983;219:979-80. CrossRef PubMed
  7.  
  8. Majd S, Power JH, Grantham HJ. Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways. BMC Neurosci. 2015;16:69. CrossRef PubMed PubMedCentral
  9.  
  10. Picard M, McManus MJ. Mitochondrial signaling and neurodegeneration. Mitochondria dysfunction in neurodegenerative disorders. Springer Int Publishing. 2016; 107-37. CrossRef  
  11. Rozova EV, Mankovskaya IN, Karasevich NV, Karaban I.N. Mitochondrial dysfunction as a characteristic of multi-organ pathology in Parkinson's disease: clinical and experimental research. Parkinson's disease and movement disorders (Manual for Physicians). Moscow, 2017;42-45. [Russian].
  12.  
  13. Talanov SA, Kotsyuruba AV, Korkach YuP, Sagach VF. Oxidative stress in cardiovascular system of rats with chronic deficit of cerebral dopamine. Fiziol Zh. 2009;55(4):32-40. [Ukrainian]. PubMed
  14.  
  15. Rozova KV, Mankovska IM, Gonchar OO, Drevytska TI, Karaban IM, Karasevich NV. The corrective influence of Capicor in experimental parkinsonism and Parkinson's disease. Ukr Visn Psykhonevrol. 2017;25 (1):102-03. [Ukrainian].
  16.  
  17. Milyukhina IV, Abdurasulova IN, Korzhevsky DE, Climenko VM. Expressiveness of the Parkinson's disease symptoms in rats under different modes of rotenone injection. Parkinson's disease and movement disorders (Manual for Physicians). Moscow, 2017;380-81. [Russian].
  18.  
  19. Chance B, Williams G. The respiratory chain and oxidative phosphorylation. Adv Enzymol. 1956; 17: 65-134. CrossRef  
  20. Estabrook RW. Mitochondrial respiratory control and the polarographic measurement of ADP/O ratios. Methods Enzymol. 1967;10:41-7. CrossRef  
  21. Buege J., Aust S., Microsomal lipid peroxidation. Methods Enzymol. 1978; LII: 302-08. CrossRef  
  22. Anderson M. Determination of glutathione and glutathione Material nadiishov do redaktsii 10.05.2018 disulfide in biological samples. Methods Enzymol. 1985; 113: 548-51. CrossRef  
  23. Putilina F.E. Biochemical assay of glutathione enzymes. Methods Biochem.1982; 1: 174-6.
  24.  
  25. Misra H, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay superoxide dismutase. J Biol Chem. 1972; 247(10): 3170-5. PubMed
  26.  
  27. Karupu VYa. The electron microscopy. K.:High school; 1984. [Russian].
  28.  
  29. Osipov VP, Lukyanova EM, Antipkin YuG, Brusilova EM, Marushko RV. The technique of statistical processing of medical information in scientific research. K: Planet of people; 2002. [Russian].
  30.  
  31. Dickinson D, Forman H. Cellular glutathione and thiols metabolism. Biochem Pharmacol. 2002; 64: 1019-26. CrossRef  
  32. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol. 2000;62:649. CrossRef  
  33. Zeevalk G, Razmpour R, Bernard L. Glutathione and Parkinson's disease: Is this the elephant in the room? Biomed Pharmacotherapy. 2008;62:236-49. CrossRef PubMed
  34.  
  35. Burbulla LF, Song P, Mazzulli JR, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science. 2017; 357(6357):1255-61. CrossRef PubMed
  36.  
  37. Mankovska IM, Rozova KV, Gonchar OO, Nosar VI, Bratus LV, Drevitska TI, Karasevich NV, Karaban IM. Effect of Capicor on the Parkinson's disease pathogenic links. Fiziol Zh. 2018;64(1):16-24. [Ukrainian]. CrossRef  
  38. Artyushkova EV. Increase in the level of gamma-buturobetaine - a pharmacological target for the correction of endothelial dysfunction. Kuban Sci Med Bul. 2009;(4): 72-5. [Russian].
  39.  
  40. Inden M, Kitamura Y, Takeuchi H. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem. 2007;101:1491-1504. CrossRef PubMed
  41.  
  42. Clements CM, McNally, Conti BJ, et al. DJ-1, a cancerand Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA. 2006;103:15091-96. CrossRef PubMed PubMedCentral

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.